EMA Authorised: Onpattro (patisiran sodium) — Alnylam Netherlands B.V.

View source ↗

Summary

The European Medicines Agency authorised Onpattro (patisiran) for familial hereditary transthyretin-mediated amyloidosis with orphan designation and accelerated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Amyloidosis
• Hereditary Transthyretin-mediated Amyloidosis

Drugs mentioned

• Onpattro (patisiran)

Snippet

Status: Authorised. Therapeutic area: Amyloidosis, Familial. MAH: Alnylam Netherlands B.V.. Decision date: 24/03/2025. Orphan medicine. Accelerated assessment